<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04431466</url>
  </required_header>
  <id_info>
    <org_study_id>IFORS</org_study_id>
    <nct_id>NCT04431466</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19</brief_title>
  <acronym>IFORS</acronym>
  <official_title>Phase 2 Clinical Trial to Compare the Efficacy and Safety of Different Doses of Ivermectin in Patients Diagnosed With the New Coronavirus Infection (SARS-CoV-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal de Sao Carlos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Federal de Sao Carlos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In December 2019, a group of patients with pneumonia of unknown cause was linked to a&#xD;
      wholesale seafood market in Wuhan, China. The genetic analysis of samples from the lower&#xD;
      respiratory tract of these patients indicated a new coronavirus as the causative agent, which&#xD;
      was named SARS-CoV-2. The virus spread rapidly to more than 45 countries, including Brazil,&#xD;
      causing an international alarm. However, in spite of its epidemiological magnitude, so far,&#xD;
      there is no antiviral treatment or vaccine approved for the treatment of this infection. With&#xD;
      about 15% to 20% of SARS-CoV-2 patients suffering from serious illnesses and overburdened&#xD;
      hospitals, therapeutic options are desperately needed. So, instead of creating compounds from&#xD;
      scratch that can take years to develop and test, researchers and public health agencies have&#xD;
      sought to redirect drugs already approved for other diseases and known to be widely safe. In&#xD;
      this context, the analysis of the international literature shows the existence of an in vitro&#xD;
      antiviral activity of ivermectin against SARS-CoV-2. However, there are no studies that have&#xD;
      evaluated its clinical effectiveness in patients diagnosed with SARS-CoV-2 infection.&#xD;
      Therefore, and considering this knowledge gap, the present study aims to determine the&#xD;
      clinical efficacy and safety of different doses of ivermectin in patients diagnosed with&#xD;
      SARS-CoV-2 infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Preliminary data from a pilot study suggest that the administration of ivermectin in patients&#xD;
    with SARS-CoV-2 is safe, reducing symptoms and viral load. The antiviral effects of ivermectin&#xD;
    appear to depend on the dose administered.&#xD;
  </why_stopped>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Actual">December 1, 2020</completion_date>
  <primary_completion_date type="Actual">December 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Undetectable viral load during 7 days of follow-up.</measure>
    <time_frame>7 days following intervention</time_frame>
    <description>Proportion of patients who achieved undetectable viral load during 7 days of follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral load variation in the nasopharyngeal swab.</measure>
    <time_frame>7 days following intervention.</time_frame>
    <description>Viral load variation in the nasopharyngeal swab during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to undetectable SARS-CoV-2 viral load in the nasopharyngeal swab.</measure>
    <time_frame>7 days following intervention.</time_frame>
    <description>Variation of serum lymphocyte counts during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Self-reported Adverse Events</measure>
    <time_frame>28 days following intervention.</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events as assessed by clinical history and physical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Laboratory-based Adverse Events</measure>
    <time_frame>28 days following intervention.</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events as assessed by laboratory tests</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Coronavirus Infection</condition>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care (SOC) treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOC plus ivermectin 100 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SOC plus ivermectin 100 mcg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOC plus ivermectin 200 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SOC plus ivermectin 200 mcg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOC plus ivermectin 400 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SOC plus ivermectin 400 mcg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <description>SOC plus different dosing regimens of Ivermectin</description>
    <arm_group_label>SOC plus ivermectin 100 mcg/kg</arm_group_label>
    <arm_group_label>SOC plus ivermectin 200 mcg/kg</arm_group_label>
    <arm_group_label>SOC plus ivermectin 400 mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Standard treatment for COVID-19</description>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of infection by SARS-CoV-2:&#xD;
&#xD;
               1. symptoms of acute respiratory tract infection (sudden onset of at least one of&#xD;
                  the following: cough, fever, shortness of breath) and biomolecular diagnosis of&#xD;
                  SARS-CoV-2 infection; OR&#xD;
&#xD;
               2. any acute respiratory disease AND biomolecular diagnosis of SARS-CoV-2 infection;&#xD;
                  OR&#xD;
&#xD;
               3. severe acute respiratory infection (fever and at least one sign / symptom of&#xD;
                  respiratory disease eg cough, fever, shortness of breath) AND in need of&#xD;
                  hospitalization AND biomolecular diagnosis of SARS-CoV-2 infection;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status score 0 to 1;&#xD;
&#xD;
          -  National Early Warning Score 0 to 4;&#xD;
&#xD;
          -  Ability to understand and consent to participate in this clinical trial, manifested by&#xD;
             signing the Informed Consent Form (ICF).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to ingest / absorb the study drug orally through spontaneous ingestion or&#xD;
             use of gastro / enteral tubes;&#xD;
&#xD;
          -  Any finding of clinical observation (history / physical evaluation) that is&#xD;
             interpreted by the investigating physician as a risk to participate in the trial;&#xD;
&#xD;
          -  Any laboratory test findings that the investigating physician considers as a risk to&#xD;
             the research participant as to his / her participation in the clinical study;&#xD;
&#xD;
          -  Any ECG examination finding that the investigating physician considers as a risk to&#xD;
             the research participant as to his / her participation in the trial;&#xD;
&#xD;
          -  Known hypersensitivity to the components of the drugs used during the study;&#xD;
&#xD;
          -  Women in pregnancy or breastfeeding;&#xD;
&#xD;
          -  Body weight less than 15kg;&#xD;
&#xD;
          -  Estimated glomerular filtration rate (CKD-Epidemiology Collaboration, CKD-EPI) &lt;30 mL&#xD;
             / min;&#xD;
&#xD;
          -  Aspartate aminotransaminase (AST) or alanine aminotransaminase (ALT)&gt; 5 times the&#xD;
             upper limit of normality;&#xD;
&#xD;
          -  Refusal to participate;&#xD;
&#xD;
          -  Refusal to sign the informed consent form.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrique Pott Junior, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade Federal de Sao Carlos</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Univeristário da Universidade Federal de São Carlos (HU-UFSCar)</name>
      <address>
        <city>São Carlos</city>
        <state>São Paulo</state>
        <zip>13565-905</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitário da Universidade Federal de São Carlos (HU-UFSCar)</name>
      <address>
        <city>São Carlos</city>
        <state>São Paulo</state>
        <zip>13566-448</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www2.ebserh.gov.br/web/hu-ufscar</url>
    <description>Hospital Universitário da UFSCar</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 10, 2020</study_first_submitted>
  <study_first_submitted_qc>June 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Federal de Sao Carlos</investigator_affiliation>
    <investigator_full_name>Henrique Pott Junior</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>coronavirus infections</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>COVID-19</keyword>
  <keyword>ivermectin</keyword>
  <keyword>clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

